ArticleScientific reports2025
Ribosomal protein L5 induces cellular senescence via p53-p21-pRb pathway to mediate relapse of acute myeloid leukemia.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Identification and validation of lymphangiogenesis-related genes for predicting acute myeloid leukemia prognosis: insights from bulk RNA sequencing and single-cell RNA sequencing analyses.Clinical and experimental medicine · 2026Article
- Immune monitoring for relapse of acute myeloid leukemia after allogeneic stem cell transplantation in clinical laboratories.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Cellular senescence plays a critical role in the relapse of acute myeloid leukemia (AML), yet the underlying mechanisms remain incompletely understood. Here, we investigated the function of ribosomal protein L5 (RPL5) in mediating cellular senescence and its impact on AML relapse. In relapsed AML patients, the proportion of senescent cells and the expression of RPL5 were elevated, compared to patients at newly diagnosised or in complete remission, suggesting a potential link between RPL5 and AML relapse. Following chemotherapy induction, a cellular senescence model was constructed using KG-1 A cells, with RPL5 expression significantly elevated. Knockdown of RPL5 suppressed cellular senescence and enhanced apoptosis, possibly due to different regulatory mechanisms for cell proliferation and senescence. Moreover, downregulation of RPL5 mitigated chemotherapy-induced senescence and improved the response of AML cells to chemotherapy drug. Mechanistically, RPL5 regulated cellular senescence via the p53-p21-pRb pathway and its downregulation led to a reduction in senescence-related protein expression levels. These findings suggest that RPL5 plays a critical role in mediating cellular senescence and chemotherapy response in AML, providing insights into novel therapeutic strategies for overcoming chemotherapy resistance and preventing disease relapse. Future studies may explore RPL5-targeted therapies and assess their clinical applicability in AML.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.